Scientific publications
Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
Munárriz J (1), Reynés G (2,3), Sánchez-Lorenzo L (4), Esteban E (5), Basterretxea L (6), de Avila-Lizárraga L (7), Climent MA (8), Juan-Fita MJ (8), Escoín C (9), Puente J (10), Cassinello J (11), Vázquez S (12), Chirivella I (13).
PURPOSE:
The aim of this multicenter study was to evaluate the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib retreatment.
METHODS:
Clinical data from patients treated with sunitinib rechallenge in nine Spanish centers were retrospectively analyzed. All patients received first-line sunitinib until progression or intolerance, followed by one or more successive drugs and rechallenge with sunitinib thereafter.
RESULTS:
Thirty-seven patients were included. At first-line treatment, objective response rate (ORR) was 69.4% and median progression-free survival (PFS) was 19.4 months. At rechallenge, ORR was 27.2% and 39.4% of patients obtained stabilization of disease. Median PFS was 6.2 months. Clinical benefit was obtained by 21 patients (75%) with > 6-month interval between sunitinib treatments and by 1 patient (20%) among those with ≤ 6-month interval (P = 0.016). Hemoglobin levels ≥ lower level of normal were associated with clinical benefit (P = 0.019) and with PFS (P = 0.004). Median overall survival from start of first-line sunitinib was 52.7 months. No new adverse events were observed at rechallenge.
CONCLUSIONS:
Sunitinib rechallenge is a feasible treatment option for selected patients with mRCC.
CITATION Cancer Chemother Pharmacol. 2019 Oct;84(4):781-789. doi: 10.1007/s00280-019-03913-3. Epub 2019 Jul 31.
Our authors
